Abstract
Ovarian cancer is typically an aggressive disease, often diagnosed at advanced stages. For many patients treatment regimens are intensive, including both surgery and chemotherapy with a high risk of recurrence in subsequent months or years. Understandably the serious nature of ovarian malignancies and their poor prognosis have led researchers to consider the psychological consequences of the disease. In addition, with around 5–10 % of these cancers being hereditary, a number of questions are raised about how patients and family members understand and cope with decisions surrounding screening and the discovery of genetic predispositions.
To date a variety of quantitative and qualitative studies have assessed the psychological implications of ovarian cancer. In this chapter the findings of this research are discussed. Although there are a number of limitations to the studies conducted, including a paucity of longitudinal research, evidence exists for associations between increased psychological distress and younger age at diagnosis, advanced disease, poor perceived social support and worse physical functioning. The positive impact of the cancer experience has also been documented, with patients reporting changes to their priorities and a greater appreciation for life. Research on the impact of genetic testing for hereditary ovarian cancer indicates that heightened levels of distress are experienced in the period surrounding test results though these frequently decrease over time. Qualitative investigations highlight the complexity of communication and decision making in families where members are at risk of inherited ovarian cancer.
National guidelines for the clinical management of ovarian cancer include recommendations for psychosocial care. Although these outline how patients should be supported with adequate information provision and access to psychological services, the extent to which guidance is effectively translated into routine care is not clear. Ideally more systematic strategies for detecting and managing psychological distress across the disease trajectory are needed to ensure patients obtain appropriate and timely support from specialist services.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Distress Management Version 2.2013. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed 9 Aug 2013
Zabora J, BrintzenhofeSzoc K, Curbow B, Hooker C, Piantadosi S. The prevalence of psychological distress by cancer site. Psychooncology. 2001;10(1):19–28.
Fann JR, Thomas-Rich AM, Katon WJ, et al. Major depression after breast cancer: a review of epidemiology and treatment. Gen Hosp Psychiatry. 2008;30(2):112–26.
Watson M, Haviland JS, Greer S, Davidson J, Bliss JM. Influence of psychological response on survival in breast cancer: a population-based cohort study. Lancet. 1999;354(9187):1331–6.
Carlson LE, Bultz BD. Benefits of psychosocial oncology care: improved quality of life and medical cost offset. Health Qual Life Outcomes. 2003;1:8.
Simpson JS, Carlson LE, Trew ME. Effect of group therapy for breast cancer on healthcare utilization. Cancer Pract. 2001;9(1):19–26.
Cancer Research UK. Ovarian cancer survival statistics. http://info.cancerresearchuk.org/cancerstats/types/ovary/survival/#stage. Accessed 01 Dec 2011.
Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet. 2009;374(9698):1371–82.
Casey C, Chen LM, Rabow M. Symptom management in gynecologic malignancies. Expert Rev Anticancer Ther. 2011;11(7):1077–89.
Kayl AE, Meyers CA. Side-effects of chemotherapy and quality of life in ovarian and breast cancer patients. Curr Opin Obstet Gynecol. 2006;18(1):24–8.
Portenoy RK, Kornblith AB, Wong G, et al. Pain in ovarian-cancer patients - prevalence, characteristics, and associated symptoms. Cancer. 1994;74(3):907–15.
Price MA, Zachariae R, Butow PN, et al. Prevalence and predictors of insomnia in women with invasive ovarian cancer: anxiety a major factor. Eur J Cancer. 2009;45(18):3262–70.
Sun CC, Bodurka DC, Donato ML, et al. Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time? Gynecol Oncol. 2002;87(1):118–28.
National Cancer Institute. PDQ® Cancer Information Summary Genetics of Breast and Ovarian Cancer (PDQ®) - Health Professional. http://www.cancer.gov/cancertopics/pdq/genetics/breast-and-ovarian/healthprofessional. Accessed 01 Dec 2011.
Vasen HFA, Stormorken A, Menko FH, et al. MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol. 2001;19(20):4074–80.
Manchanda R, Menon U, Michaelson-Cohen R, Beller U, Jacobs I. Hereditary non-polyposis colorectal cancer or Lynch syndrome: the gynaecological perspective. Curr Opin Obstet Gynecol. 2009;21(1):31–8.
Arden-Close E, Gidron Y, Moss-Morris R. Psychological distress and its correlates in ovarian cancer: a systematic review. Psychooncology. 2008;17(11):1061–72.
Hipkins J, Whitworth M, Tarrier N, Jayson G. Social support, anxiety and depression after chemotherapy for ovarian cancer: a prospective study. Br J Health Psychol. 2004;9(Pt 4):569–81.
Kornblith AB, Thaler HT, Wong G, et al. Quality of life of women with ovarian cancer. Gynecol Oncol. 1995;59(2):231–42.
Bodurka-Bevers D, Basen-Engquist K, Carmack CL, et al. Depression, anxiety, and quality of life in patients with epithelial ovarian cancer. Gynecol Oncol. 2000;78(3 Pt 1):302–8.
Goncalves V, Jayson G, Tarrier N. A longitudinal investigation of psychological morbidity in patients with ovarian cancer. Br J Cancer. 2008;99(11):1794–801.
Hodgkinson K, Butow P, Fuchs A, et al. Long-term survival from gynecologic cancer: psychosocial outcomes, supportive care needs and positive outcomes. Gynecol Oncol. 2007;104(2):381–9.
Norton TR, Manne SL, Rubin S, et al. Prevalence and predictors of psychological distress among women with ovarian cancer. J Clin Oncol. 2004;22(5):919–26.
Norton TR, Manne SL, Rubin S, et al. Ovarian cancer patients’ psychological distress: the role of physical impairment, perceived unsupportive family and friend behaviors, perceived control, and self-esteem. Health Psychol. 2005;24(2):143–52.
Wenzel LB, Donnelly JP, Fowler JM, et al. Resilience, reflection, and residual stress in ovarian cancer survivorship: a gynecologic oncology group study. Psychooncology. 2002;11(2):142–53.
Petersen RW, Graham G, Quinlivan JA. Psychologic changes after a gynecologic cancer. J Obstet Gynaecol Res. 2005;31(2):152–7.
Boscaglia N, Clarke DM, Jobling TW, Quinn MA. The contribution of spirituality and spiritual coping to anxiety and depression in women with a recent diagnosis of gynecological cancer. Int J Gynecol Cancer. 2005;15(5):755–61.
Molassiotis A, Chan CW, Yam BM, Chan SJ. Quality of life in Chinese women with gynaecological cancers. Support Care Cancer. 2000;8(5):414–22.
Parker PA, Kudelka A, Basen-Engquist K, Kavanagh J, de Moor J, Cohen L. The associations between knowledge, CA125 preoccupation, and distress in women with epithelial ovarian cancer. Gynecol Oncol. 2006;100(3):495–500.
Ponto JA, Ellington L, Mellon S, Beck SL. Predictors of adjustment and growth in women with recurrent ovarian cancer. Oncol Nurs Forum. 2010;37(3):357–64.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: APA; 1994. DSM–IV.
Goncalves V, Jayson G, Tarrier N. A longitudinal investigation of posttraumatic stress disorder in patients with ovarian cancer. J Psychosom Res. 2011;70(5):422–31.
Matulonis UA, Kornblith A, Lee H, et al. Long-term adjustment of early-stage ovarian cancer survivors. Int J Gynecol Cancer. 2008;18(6):1183–93.
Mirabeau-Beale KL, Kornblith AB, Penson RT, et al. Comparison of the quality of life of early and advanced stage ovarian cancer survivors. Gynecol Oncol. 2009;114(2):353–9.
Posluszny DM, Edwards RP, Dew MA, Baum A. Perceived threat and PTSD symptoms in women undergoing surgery for gynecologic cancer or benign conditions. Psychooncology. 2011;20(7):783–7.
Bisseling KCHM, Kondalsamy-Chennakesavan S, Bekkers RLM, Janda M, Obermair A. Depression, anxiety and body image after treatment for invasive stage one epithelial ovarian cancer. Aust N Z J Obstet Gynaecol. 2009;49(6):660–6.
Miller RE, Rustin GJ. How to follow-up patients with epithelial ovarian cancer. Curr Opin Oncol. 2010;22(5):498–502.
Jordens CF, Morrell B, Harnett P, Hobbs K, Mason C, Kerridge IH. Cancergazing? CA125 and post-treatment surveillance in advanced ovarian cancer. Soc Sci Med. 2010;71(9):1548–56.
Karam AK, Karlan BY. Ovarian cancer: the duplicity of CA125 measurement. Nat Rev Clin Oncol. 2010;7(6):335–9.
Oskay-Oezcelik G, du Bois A, Fasching PA, et al. What do patients think about CA-125 monitoring in the follow-up? Results from a multicenter trial in 1,060 patients with ovarian cancer. J Clin Oncol. 2009;27(15s):5522.
Markman M, Peterson J, Belland A, Burg K. CA-125 monitoring in ovarian cancer: patient survey responses to the results of the MRC/EORTC CA-125 surveillance trial. Oncology. 2010;78:1–2.
Kew F, Galaal K, Bryant A, Naik R. Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatment. Cochrane Database Syst Rev. 2011;(6):CD006119.
Power J, Brown L, Ritvo P. A qualitative study examining psychosocial distress, coping, and social support across the stages and phases of epithelial ovarian cancer. Health Care Women Int. 2008;29(4):366–83.
Australian Ovarian Cancer Study. http://www.aocstudy.org/hp_programme.aspl. Accessed 01 Dec 2011.
Price MA, Butow PN, Costa DSJ, et al. Prevalence and predictors of anxiety and depression in women with invasive ovarian cancer and their caregivers. Med J Aust. 2010;193(5):S52–7.
Mahdi H, Swensen RE, Munkarah AR, et al. Suicide in women with gynecologic cancer. Gynecol Oncol. 2011;122(2):344–9.
Jansen L, Hoffmeister M, Chang-Claude J, Brenner H, Arndt V. Benefit finding and post-traumatic growth in long-term colorectal cancer survivors: prevalence, determinants, and associations with quality of life. Br J Cancer. 2011;105(8):1158–65.
Mols F, Vingerhoets AJJM, Coebergh JWW, van de Poll-Franse LV. Well-being, posttraumatic growth and benefit finding in long-term breast cancer survivors. Psychol Health. 2009;24(5):583–95.
Stewart DE, Wong F, Duff S, Melancon CH, Cheung AM. “What doesn’t kill you makes you stronger”: an ovarian cancer survivor survey. Gynecol Oncol. 2001;83(3):537–42.
Ponto JA, Barton D. Husbands ‘perspective of living with wives’ ovarian cancer. Psychooncology. 2008;17(12):1225–31.
Lutgendorf SK, Anderson B, Ullrich P, et al. Quality of life and mood in women with gynecologic cancer: a one year prospective study. Cancer. 2002;94(1):131–40.
Carey M, Noble N, Sanson-Fisher R, Mackenzie L. Identifying psychological morbidity among people with cancer using the Hospital Anxiety and Depression Scale: time to revisit first principles? Psychooncology. 2011;21(3):229–38. doi:10.1002/pon.2057. Early view (online version).
Ziegler L, Hill K, Neilly L, et al. A systematic review of self-report measure performance at key stages of the cancer illness trajectory. J Pain Symptom Manage. 2011;41(3):619–36.
Armes J, Crowe M, Colbourne L, et al. Patients’ supportive care needs beyond the end of cancer treatment: a prospective, longitudinal survey. J Clin Oncol. 2009;27(36):6172–9.
Beesley V, Eakin E, Steginga S, Aitken J, Dunn J, Battistutta D. Unmet needs of gynaecological cancer survivors: implications for developing community support services. Psychooncology. 2008;17(4):392–400.
Harrison JD, Young JM, Price MA, Butow PN, Solomon MJ. What are the unmet supportive care needs of people with cancer? A systematic review. Support Care Cancer. 2009;17(8):1117–28.
Merckaert I, Libert Y, Messin S, Milani M, Slachmuylder JL, Razavi D. Cancer patients’ desire for psychological support: prevalence and implications for screening patients’ psychological needs. Psychooncology. 2010;19(2):141–9.
National Institute of Health & Clinical Excellence. Improving supportive and palliative care for adults with cancer: the manual. London: National Institute for Clinical Excellence; 2004.
National Breast Cancer Centre and the National Cancer Control Initiative. Clinical practice guidelines for the psychosocial care of adults with cancer. Camperdown: National Breast Cancer Centre; 2003.
National Cancer Action Team. Connected: National communication skills training. 2011; http://www.connected.nhs.uk/.
Sharpe M, Strong V, Allen K, et al. Major depression in outpatients attending a regional cancer centre: screening and unmet treatment needs. Br J Cancer. 2004;90(2):314–20.
Passik SD, Dugan W, McDonald MV, Rosenfeld B, Theobald DE, Edgerton S. Oncologists’ recognition of depression in their patients with cancer. J Clin Oncol. 1998;16(4):1594–600.
Fallowfield L, Ratcliffe D, Jenkins V, Saul J. Psychiatric morbidity and its recognition by doctors in patients with cancer. Br J Cancer. 2001;84(8):1011–5.
McLachlan SA, Allenby A, Matthews J, et al. Randomized trial of coordinated psychosocial interventions based on patient self-assessments versus standard care to improve the psychosocial functioning of patients with cancer. J Clin Oncol. 2001;19(21):4117–25.
Velikova G, Booth L, Smith AB, et al. Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol. 2004;22(4):714–24.
Strong V, Waters R, Hibberd C, et al. Management of depression for people with cancer (SMaRT oncology 1): a randomised trial. Lancet. 2008;372(9632):40–8.
Detmar SB, Muller MJ, Schornagel JH, Wever LDV, Aaronson NK. Health-related quality-of-life assessments and patient-physician communication - a randomized controlled trial. JAMA. 2002;288(23):3027–34.
Jacobsen PB, Ransom S. Implementation of NCCN distress management guidelines by member institutions. J Natl Compr Canc Netw. 2007;5(1):99–103.
Mitchell AJ, Kaar S, Coggan C, Herdman J. Acceptability of common screening methods used to detect distress and related mood disorders-preferences of cancer specialists and non-specialists. Psychooncology. 2008;17(3):226–36.
Absolom K, Holch P, Pini S, et al. The detection and management of emotional distress in cancer patients: the views of health care professionals. Psychooncology. 2011;20(6):601–8.
Gessler S, Low J, Daniells E, et al. Screening for distress in cancer patients: is the distress thermometer a valid measure in the UK and does it measure change over time? A prospective validation study. Psychooncology. 2008;17(6):538–47.
Johnson RL, Gold MA, Wyche KF. Distress in women with gynecologic cancer. Psychooncology. 2010;19(6):665–8.
McCorkle R, Dowd M, Ercolano E, et al. Effects of a nursing intervention on quality of life outcomes in post-surgical women with gynecological cancers. Psychooncology. 2009;18(1):62–70.
Henry M, Cohen SR, Lee V, et al. The Meaning-Making intervention (MMi) appears to increase meaning in life in advanced ovarian cancer: a randomized controlled pilot study. Psychooncology. 2010;19(12):1340–7.
Hersch J, Juraskova I, Price M, Mullan B. Psychosocial interventions and quality of life in gynaecological cancer patients: a systematic review. Psychooncology. 2009;18(8):795–810.
McAllister M, Davies L, Payne K, Nicholls S, Donnai D, MacLeod R. The emotional effects of genetic diseases: implications for clinical genetics. Am J Med Genet A. 2007;143A(22):2651–61.
Hopwood P. Psychosocial aspects of risk communication and mutation testing in familial breast-ovarian cancer. Curr Opin Oncol. 2005;17(4):340–4.
Vadaparampil ST, Wey JP, Kinney AY. Psychosocial aspects of genetic counseling and testing. Semin Oncol Nurs. 2004;20(3):186–95.
Cull A, Fry A, Rush R, Steel CM. Cancer risk perceptions and distress among women attending a familial ovarian cancer clinic. Br J Cancer. 2001;84(5):594–9.
Erlick Robinson G, Rosen BP, Bradley LN, et al. Psychological impact of screening for familial ovarian cancer: reactions to initial assessment. Gynecol Oncol. 1997;65(2):197–205.
Wardle FJ, Collins W, Pernet AL, Whitehead MI, Bourne TH, Campbell S. Psychological impact of screening for familial ovarian cancer. J Natl Cancer Inst. 1993;85(8):653–7.
Schwartz MD, Peshkin BN, Hughes C, Main D, Isaacs C, Lerman C. Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic-based sample. J Clin Oncol. 2002;20(2):514–20.
Watson M, Foster C, Eeles R, et al. Psychosocial impact of breast/ovarian (BRCA1/2) cancer-predictive genetic testing in a UK multi-centre clinical cohort. Br J Cancer. 2004;91(10):1787–94.
Wood ME, Mullineaux L, Rahm AK, Fairclough D, Wenzel L. Impact of BRCA1 testing on women with cancer: a pilot study. Genet Test. 2000;4(3):265–72.
Hamilton JG, Lobel M, Moyer A. Emotional distress following genetic testing for hereditary breast and ovarian cancer: a meta-analytic review. Health Psychol. 2009;28(4):510–8.
Baum A, Friedman AL, Zakowski SG. Stress and genetic testing for disease risk. Health Psychol. 1997;16(1):8–19.
Hallowell N, Foster C, Eeles R, Ardern-Jones A, Watson M. Accommodating risk: responses to BRCA1/2 genetic testing of women who have had cancer. Soc Sci Med. 2004;59(3):553–65.
Germino BB, Fife BL, Funk SG. Cancer and the partner relationship: what is its meaning? Semin Oncol Nurs. 1995;11(1):43–50.
Pistrang N, Barker C. The partner relationship in psychological response to breast-cancer. Soc Sci Med. 1995;40(6):789–97.
van Oostrom I, Meijers-Heijboer H, Lodder LN, et al. Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study. J Clin Oncol. 2003;21(20):3867–74.
Mellon S, Berry-Bobovski L, Gold R, Levin N, Tainsky MA. Communication and decision-making about seeking inherited cancer risk information: findings from female survivor-relative focus groups. Psychooncology. 2006;15(3):193–208.
Dancyger C, Smith JA, Jacobs C, Wallace M, Michie S. Comparing family members’ motivations and attitudes towards genetic testing for hereditary breast and ovarian cancer: a qualitative analysis. Eur J Hum Genet. 2010;18(12):1289–95.
Griffiths SE, Lopes T, Edmondson RJ. The role of prophylactic salpingo-oophorectomy in women who carry mutations of the BRCA genes. Obstet Gynecol. 2005;7:23–7.
Oei AL, Massuger LF, Bulten J, Ligtenberg MJ, Hoogerbrugge N, de Hullu JA. Surveillance of women at high risk for hereditary ovarian cancer is inefficient. Br J Cancer. 2006;94(6):814–9.
Van Nagell Jr JR, DePriest PD, Reedy MB, et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol. 2000;77(3):350–6.
Woodward ER, Sleightholme HV, Considine AM, Williamson S, McHugo JM, Cruger DG. Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective. BJOG. 2007;114(12):1500–9.
UK Familial Ovarian Cancer Screening Study (UK FOCSS). 2011; http://www.instituteforwomenshealth.ucl.ac.uk/academic_research/gynaecologicalcancer/gcrc/ukfocss. Accessed 25 Nov 2011.
Lifford KJ, Fraser L, Rosenthal AN, et al. Withdrawal from familial ovarian cancer screening for surgery: findings from a psychological evaluation study (PsyFOCS). Gynecol Oncol. 2011;124(1):158–63.
Miller SM, Roussi P, Daly MB, Scarpato J. New strategies in ovarian cancer: uptake and experience of women at high risk of ovarian cancer who are considering risk-reducing salpingo-oophorectomy. Clin Cancer Res. 2010;16(21):5094–106.
NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. JAMA. 1995;273:491–7.
Fry A, Busby-Earle C, Rush R, Cull A. Prophylactic oophorectomy versus screening: psychosocial outcomes in women at increased risk of ovarian cancer. Psychooncology. 2001;10(3):231–41.
Michelsen TM, Dorum A, Dahl AA. A controlled study of mental distress and somatic complaints after risk-reducing salpingo-oophorectomy in women at risk for hereditary breast ovarian cancer. Gynecol Oncol. 2009;113(1):128–33.
Touboul C, Uzan C, Ichante JL, et al. Factors associated with altered long-term well-being after prophylactic salpingo-oophorectomy among women at increased hereditary risk for breast and ovarian cancer. Oncologist. 2011;16(9):1250–7.
Scottish Intercollegiate Guidelines Network. Epithelial ovarian cancer: a national clinical guideline. Edinburgh: Royal College of Physicians; 2003.
UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). 2011; http://www.instituteforwomenshealth.ucl.ac.uk/academic_research/gynaecologicalcancer/gcrc/ukctocs. Accessed 25 Nov 2011.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Absolom, K., Takeuchi, E., Hall, G., Velikova, G. (2014). Psychological Aspects of Hereditary and Non-hereditary Ovarian Cancer. In: Farghaly, S. (eds) Advances in Diagnosis and Management of Ovarian Cancer. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-8271-0_13
Download citation
DOI: https://doi.org/10.1007/978-1-4614-8271-0_13
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4614-8270-3
Online ISBN: 978-1-4614-8271-0
eBook Packages: MedicineMedicine (R0)